Emerging Markets Earnings Roundup: Johnson & Johnson (Part 1)
This article was originally published in PharmAsia News
Executive Summary
Second quarter earnings from Johnson & Johnson shed light on the view on biosimilar launches of Remicade and how the company hopes to streamline its varied arms abroad.